Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092014
Status:
COMPLETED
Last Update Posted:
2024-04-03
First Post:
2004-09-21
Brief Title:
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis MK-0217-211
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A 12-Month Extension to A Randomized Double-Blind Double-Dummy Parallel-Group Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FACT
Brief Summary:
This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis The primary hypothesis for this study is that in postmenopausal women with osteoporosis treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density BMD at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_016 | OTHER | Protocol number | None |